Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

2012661 citationsJournal Articlebronze Open Access

Authors

Evan A. Stein · Louisville Metabolic and Atherosclerosis Research Center

Scott Mellis · Regeneron (United States)

George D. Yancopoulos · Regeneron (United States)

Neil Stahl · Regeneron (United States)

Douglas Logan · Medpace (United States)

William Smith · University of Tennessee at Knoxville

Eleanor Lisbon

Abstract

In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).

Topics & Keywords

Lipoproteins and Cardiovascular Health Protein Kinase Regulation and GTPase Signaling Computational Drug Discovery Methods

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 12, pp. 1108-1118

DOI: 10.1056/nejmoa1105803

Field-Weighted Citation Impact: 93.14

Command Palette

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Authors

Abstract

Topics & Keywords

Publication Details